Clinical Research Directory

Inclusion Criteria: * Have a diagnosis of prostate cancer and be scheduled to receive radiotherapy with concurrent androgen deprivation therapy, and presence of fatigue with severity of 1/10, on a 0-10 scale for at least 2 weeks * Patient not regularly engaging in moderate aerobic exercise for \>90 minutes/week and/or vigorous aerobic exercise for \>30 minutes/week, and/ or strength training for \>/= 1 day/week * Have no clinical evidence of cognitive failure as evidenced by Memorial Delirium Assessment Scale score of \</=13 at baseline * Be aged 18 years or older * Be willing to engage in follow-up telephone calls with a research staff * Be willing to participate in the exercise programs * Have telephone access so they can be contacted by the research staff * Have a hemoglobin level of \>/= 10 g/dL within 2 weeks of enrollment * Be able to understand the description of the study and give written informed consent * Have a Zubrod performance status score of 0 to 2 * Seen at an outpatient clinic at MD Anderson Cancer Center, its Houston Area Locations (HALs) or Smith Radiation Oncology Clinic (HHS) Exclusion Criteria: * Have a major contraindication to MethylphenidateMP) (e.g., allergy/hypersensitivity to study medications or their constituents), exercise (e.g., cardiac disease), or conditions making adherence difficult as determined by the attending physician * Be currently taking MP, or have taken it within the previous 10 days * Be unable to complete the baseline assessment forms (e.g., due to language or sensory barriers) or to understand the recommendations for participation in the study * Need monoamine oxidase inhibitors, tricyclic antidepressants, or clonidine * Have glaucoma * Have severe cardiac disease (New York Heart Association functional class III or IV) * Have tachycardia and/or uncontrolled hypertension * Be currently receiving anticoagulants, anticonvulsants (phenobarbital, diphenylhydantone, primidone), phenylbutazone, and/or tricyclic drugs (imipramine, clomipramine, or desipramine).